Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Glibenclamide - AMMTeK

Next Previous
Drug Profile

Glibenclamide - AMMTeK

Alternative Names: AMGLIDIA; Amglidia; glyburide oral suspension

Latest Information Update: 02 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AMMTeK
  • Developer AMMTeK; Assistance Publique Hopitaux de Paris
  • Class Antihyperglycaemics; Benzamides; Small molecules; Sulfonylureas; Vascular disorder therapies
  • Mechanism of Action KATP channel inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Type 2 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 31 Aug 2026 Eton Pharmaceuticals plans a bioavailability study for the Glibenclamide, in August 2026
  • 14 Aug 2026 Eton Pharmaceuticals anticipates the approval and launch in Type 2 diabetes mellitus in 2027
  • 13 Aug 2026 Glibenclamide (AMGLIDIA®) receives Fast track status from the US FDA for Type 2 diabetes mellitus

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top